Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Studies indicate that miR (show MLXIP Antibodies)-182 negatively regulated Met via direct binding to the Met 3'-untranslated region (3'-UTR (show UTS2R Antibodies)).
Selective MET tyrosine kinase (show TXK Antibodies) inhibitor SAR125844 has significant antitumour activity in patients with MET-amplified non-small cell lung carcinoma.
miR (show MLXIP Antibodies)-34a reconstitution in DMPM cells significantly inhibited proliferation and tumorigenicity, induced an apoptotic response, and declined invasion ability, mainly through the down-regulation of c-MET and AXL (show AXL Antibodies) and the interference with the activation of downstream signaling.
The hepatocyte growth factor (HGF (show HGF Antibodies))-MET receptor tyrosine kinase (show RET Antibodies) signaling pathway
Crizotinib is active and well tolerated in advanced, metastatic papillary renal cell carcinoma (show MOK Antibodies) type 1, achieving objective responses and long-lasting disease control in patients with MET mutations or amplification.
Data show that cancer-associated fibroblasts (CAFs (show TBX1 Antibodies))-derived hepatocyte growth factor (HGF (show HGF Antibodies)) or recombinant HGF (show HGF Antibodies) activated c-Met/phosphoinositide 3-kinase (PI3K (show PIK3CA Antibodies))/Akt (show AKT1 Antibodies) and glucose-regulated protein 78 (GRP78 (show HSPA5 Antibodies)) signalling pathways in ovarian cancer cells.
Data show that MET is the direct target of miR (show MLXIP Antibodies)-206 in lung cancer cells.
Results indicate that miR (show MLXIP Antibodies)-329 played a pivotal role in lung cancer through inhibiting cell proliferation, migration, invasion, and promoting apoptosis by targeting oncogenic MET.
nMet accelerated HCC (show FAM126A Antibodies) tumorigenesis and metastasis via the activation of TAK1 (show MAP3K7 Antibodies)/NF-kappaB (show NFKB1 Antibodies) pathway.
Data show that afatinib resistant clones were selectively killed by knock down of ERBB3 (show ERBB3 Antibodies) + c-MET + c-KIT (show KIT Antibodies), but not by the individual or doublet knock down combinations, and the combination of afatinib with the SRC (show SRC Antibodies) family inhibitor dasatinib killed afatinib resistant H1975 cells in a greater than additive fashion.
possible cooperative role of the EGF (show EGF Antibodies) and HGF (show HGF Antibodies) pathways and indicate that cross-talk between their respective receptors may modulate mammary gland development in the cow
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene.
, HGF/SF receptor
, SF receptor
, hepatocyte growth factor receptor
, met proto-oncogene tyrosine kinase
, proto-oncogene c-Met
, scatter factor receptor
, tyrosine-protein kinase Met
, HGF receptor c-Met
, hepatocyte growth factor
, hepatoCyte growth factor receptor
, met proto-oncogene
, Hepatocyte growth factor receptor
, hepatocyte growth factor receptor-like
, Proto-oncogene c-Met
, Scatter factor receptor
, Tyrosine-protein kinase Met